Highlight
– The AID-ME trial is the first multicenter, cluster randomized clinical trial evaluating an AI-enabled clinical decision support system (CDSS) for personalized antidepressant selection.
– Patients managed with the AI-CDSS showed a significantly higher remission rate (28.6%) compared to controls (0%) and faster symptomatic improvement.
– The AI-CDSS combines deep learning predictions of individual antidepressant remission probabilities with evidence-based clinical algorithms.
– No serious adverse events were related to the CDSS, supporting its safety and feasibility in outpatient psychiatric practice.
